论文部分内容阅读
扎莫特罗(xamoterol,简称XAM)是一种选择性部分β_1受体激动剂,其综合作用是稳定心脏对交感神经兴奋的反应。即在休息和轻度体力活动时,XAM能加强心肌收缩,而在较重的体力活动时,本品能减慢心率。本文采用随机、双盲、交叉、安慰剂对照试验评价了XAM对缺血性左室功能不全的疗效。 21例心衰病人均有缺血性心脏病和心肌梗塞史,其中20例为NYHAⅡ级,1例Ⅲ级。所有病人在7～14天的安慰剂治疗期后,随机双盲接受了XAM(200mg每日2次)或安慰剂。4周后,两组交换给药治疗4周。每一治疗期末分别行运动试验及临床和超声心
Xamoterol (XAM) is a selective β 1 receptor agonist, its combined effect is to stabilize the heart’s response to sympathetic activation. That rest and mild physical activity, XAM can enhance myocardial contractions, and in heavier physical activity, the product can slow down the heart rate. This randomized, double-blind, crossover, placebo-controlled trial evaluated the efficacy of XAM on ischemic left ventricular dysfunction. Twenty-one patients with heart failure had ischemic heart disease and myocardial infarction, of which 20 were NYHA Ⅱ and 1 patient Ⅲ. All patients received a randomized double-blind XAM (200 mg twice daily) or placebo after a 7-14 day placebo treatment period. After 4 weeks, the two groups were given 4 weeks of treatment. Exercise test and clinical and echocardiography were performed at the end of each treatment period